Clinical Trial

Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

Study acronym: Hypo-M1
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 28, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-11-02; most recent amendment 2024-02-27.
Status change: Not Yet Recruiting → Recruiting 2022-11-01
Trial Details
NCT Number NCT04612907
Lead Sponsor Umeå University
Conditions Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer
Enrollment 420 participants
Start Date 2022-10-31
Primary Completion 2026-06-30 (estimated)
Study Completion 2032-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-28